Assessment of Citrullinated Myelin by ¹H-MR Spectroscopy in Early-Onset Multiple Sclerosis

References

1. ↵
   Heipertz R, Pilz H, Scholz W. The fatty acid composition of sphingomyelin from adult human cerebral white matter and changes in childhood, senium and unspecific brain damage. J Neurol 1977;216:57–65

   CrossRefPubMed
2. ↵
   Moscarello MA, Wood DD, Ackerley C, et al. Myelin in multiple sclerosis is developmentally immature. J Clin Invest 1994;94:146–54

   CrossRefPubMedWeb of Science
3. ↵
   Moscarello MA. Myelin basic protein, the executive molecule of the myelin membrane. In: Juurlink BHJ, Devon RM, Doucette JR, et al, eds. Cell Biology and Pathology of Myelin: Evolving Biological Concepts and Therapeutic Approaches. NY: Plenum;1997 :13–25
4. ↵
   Pritzker LB, Joshi S, Gowan JJ, et al. Deimination of myelin basic protein. I. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 2000;39:5324–81
5. ↵
   Wood DD, Bilbao JM, O'Connors P, et al. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996;40:18–24

   CrossRefPubMedWeb of Science
6. ↵
   Whitaker JM, Mitchell GW. A possible role for myelin basic protein in multiple sclerosis. Ann Neurol 1996;40:3–4

   CrossRefPubMedWeb of Science
7. ↵
   Anlar B, Karli-Oguz K, Yurtyapan OY, et al. Tracing immature myelin in acute disseminated encephalomyelitis. Turk J Pediatr 2006;48:197–201

   PubMed
8. ↵
   Silberstein M, Lane D, Dodd S, et al. Identification of a by-product of nitric oxide synthase activity in human acute brain injury with in vivo proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2002;23:389–92

   Abstract/FREE Full Text
9. ↵
   Moscarello MA, Mastronardi FG, Wood DD. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 2007;32:251–56

   CrossRefPubMedWeb of Science
10. ↵
    Mastronardi FG, Ackerley CA, Arsenault L, et al. Demyelination in a transgenic mouse: a model for multiple sclerosis. J Neurosci Res 1993;36:315–24

    CrossRefPubMedWeb of Science
11. ↵
    Cristofolini L, Fontana MP, Serra F, et al. Microstructural analysis of the effects of incorporation of myelin basic protein in phospholipid layers. Eur Biophys J 2005;34:1041–48

    CrossRefPubMed
12. ↵
    Shanshiashvili LV, Suknidze NC, Machaidze GG, et al. Adhesion and clustering of charge isomers of myelin basic protein at model myelin membranes. Arch Biochem Biophys 2003;419:170–77

    CrossRefPubMedWeb of Science
13. ↵
    Wood DD, Ackerley CA, Brand B, et al. Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities. Lab Invest 2008;88:354–64. Epub 2008 Jan 28

    CrossRefPubMedWeb of Science
14. ↵
    Mastronardi FG, Noor A, Wood DD, et al. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J Neurosci Res 2007;85:2006–16

    CrossRefPubMedWeb of Science
15. ↵
    Tranquill LR, Cao L, Ling NC, et al. Enhanced T cell responsiveness to citrulline-containing myelin basic protein in multiple sclerosis patients. Mult Scler 2000;6:220–25

    Abstract/FREE Full Text
16. ↵
    Brück W, Stadelman C. Pathology of the normal-appearing white matter in multiple sclerosis. In: Flippi M, Comi G, Rovaris M, eds. Normal-Appearing White and Grey Matter Damage in Multiple Sclerosis. Milan, Italy: Springer-Verlag;2004 :3–8
17. ↵
    Pike GB, De Stefano N, Narayanan S, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology 2000;215:824–30

    PubMedWeb of Science
18. ↵
    De Stefano N, Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging 2007;17 (suppl 1):31S–35S

    CrossRefPubMedWeb of Science
19. ↵
    Werring DJ, Brassat D, Droogan AG et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 2000;123:1667–76

    Abstract/FREE Full Text
20. ↵
    Vermathen P, Laxer KD, Schuff N, et al. Evidence of neuronal injury outside the medial temporal lobe in temporal lobe epilepsy: N-acetylaspartate concentration reductions detected with multisection proton MR spectroscopic imaging—initial experience. Radiology 2003;226:195–202

    PubMed
21. ↵
    Ludwin SK. The pathogenesis of multiple sclerosis: relating human pathology to experimental studies. J Neuropathol Exp Neurol 2006;65:305–18

    PubMed
22. ↵
    Barker PB, Hearshen DO, Boska MD. Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med 2001;45:765–69

    CrossRefPubMedWeb of Science
23. ↵
    De Stefano N, Narayanan S, Mortilla M, et al. Imaging axonal damage in multiple sclerosis by means of MR spectroscopy. Neurol Sci 2000;21 (4 suppl 2):S883–87

    CrossRefPubMed
24. ↵
    Narayana PA, Doyle TJ, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43:56–71

    CrossRefPubMedWeb of Science
25. ↵
    Mader I, Roser W, Kappos L, et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 2000;21:1220–27

    Abstract/FREE Full Text
26. ↵
    Vrenken H, Barkhof F, Uitdehaag BM, et al. MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 2005;53:256–66

    CrossRefPubMedWeb of Science
27. ↵
    Siger-Zajdel M, Selmaj K. Proton magnetic resonance spectroscopy of normal appearing white matter in asymptomatic relatives of multiple sclerosis patients. Eur J Neurol 2006;13:296–98

    CrossRefPubMedWeb of Science